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Abstract
Biobank operations started officially in Finland in 2013 when the Biobank Act defining and regulating biobank operations 
came into force. Since then, ten biobanks have been established and they have started to collect new prospective samples 
with broad consent. The main corpus of biobank samples, however, consists of approximately 10 million “legacy samples”. 
These are old diagnostic or research samples that were transferred to biobanks in accordance with the Biobank Act. The 
focus of this article is on ambiguities concerning these legacy samples and their transfer in terms of legality, human rights, 
autonomy, and social sustainability. We analyse the Finnish biobank operations in the context of international regulation, 
such as the European Convention of Human Rights, the Oviedo Convention, European Charter of Fundamental Rights, the 
GDPR, and EU Clinical Trials Regulation, and show that the practice of using legacy samples is at times problematic in 
relation to this regulatory framework. We argue that the prevailing interpretations of these regulations as translated into the 
Finnish biobank practices undermine the autonomy of individuals by not giving individuals a right to consent or an actionable 
right to opt-out of the transfer of these legacy samples to the biobank. This is due to the fact that individuals are not given 
effective notification of such transfers. Thus, issues regarding the legal status of the biobank samples and the social sustain-
ability of biobank operations remain a challenge for biobanks in Finland despite governmental efforts to create pioneering, 
comprehensive, and enabling legislation.
Introduction
During the first decade of this millennium, biobank legisla-
tion was prepared in Finland. This legislation was expected 
to enable biomedical research and development through new 
prospective samples collected with consent. Finnish biobank 
legislation (Biobank Act 688/2012) entered into force in 
September 2013 and was celebrated as the first comprehen-
sive modern biobank law to enable recontacting of donors 
and enhance the autonomy and privacy of individuals (Soini 
2013; Tupasela 2015; MSAH 2016; Snell and Tarkkala 
2019). Today, ten biobanks in Finland have been founded to 
meet the requirements of the law. In this way, Finland also 
defined biobanks through legislation—not all collections of 
specimens or collections of samples collected for research 
can be referred to as biobanks in terms of the law.
At the official governmental level and in the promotional 
material of Finnish biobanks, this regulatory landscape has 
been presented as an advantage for Finnish biobank opera-
tions in attracting interest and investments (e.g., Soini 2016; 
Ministry of Social Affairs and Health 2016: 5, 8; Biobanking 
in Finland 2018). Moreover, there is also an ongoing effort 
to build legislation for the health care sector to strengthen 
its potential for wider innovation purposes (see, for example, 
Ministry of Employment and Economy (MEE) 2016; Tark-
kala et al. 2019). The recent law on secondary uses of social 
and health data (552/2019) as well as the planned genome 
centre (Ministry of Social Affairs and Health [MSAH] 
2015) are part of this development. The effort to develop 
a robust and enabling legislative and regulatory environ-
ment has been used in strategy materials and innovation 
policy to underline Finnish competitiveness in biomedical 
research and development (Tarkkala et al. 2019). That is, it is 
expected that biobank operations will not only foster person-
alized medicine, but also research and development activi-
ties and innovations in biomedicine (Tarkkala 2019). Thus, 
for example, biobank collections can be utilized not only in 
research by universities, but also in different collaborations 
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between academia and commercial partners as well as solely 
for, e.g., product development by companies. However, the 
Finnish biobank legislation has been under ongoing revision 
almost from the day that it was put into force.
In practice, the current legislation and its different inter-
pretations in relation to actual biobank practices have cre-
ated an equivocal situation. The broad informed consent 
model for prospective samples was regarded as justified, 
because it was seen to merit both research and the auton-
omy of individuals, as outlined in the Government proposal 
for the Biobank Act (HE 86/2011). This followed a general 
European and international trend to regard broad consent 
as a valid and preferred model for biobanking (Master et al. 
2012). However, at the same time, when it became possible 
to start the collection of prospective samples, a transfer of 
the existing diagnostic sample collections in public hos-
pitals, research collections in universities, and the epide-
miological research collections of the National Institute of 
Health and Welfare (THL) into biobanks became possible 
without informed consent. It is the ambiguities concerning 
these older legacy samples and their transfer—both legally 
and in terms of social sustainability—that we examine in 
this article. Transfer of older collections into biobanks, 
or considering them as biobanks, has taken place in many 
countries. However, in Finland, this has created ambiguity 
in relation to how biobank practices are publicly presented 
and what collections can be transferred into biobanks in the 
first place. The case of legacy samples also brings forth the 
legislative choices Finland has made. We argue that even 
though European regulative framework puts high empha-
sis on individual rights, autonomy, and informed consent, 
Finnish biobank operations are in practice based on the 
transfer of legacy samples to biobanks, which undermines 
the autonomy of individuals, and the usage of samples is 
carried out for the most part without effectively informing 
their original donors.
Balancing individual autonomy and solidarity in scientific 
research utilizing biological materials and data has been the 
focus of ethico-legal discussion related to biomedical research 
for a long time. We believe that people’s rights to restrict con-
sent or opt-out can be respected while building safe mecha-
nisms to share data and promote research and development 
(Knoppers et al. 2014; Townend 2018; Richter et al. 2019). 
The new EU regulative framework applicable for processing 
of health-related data for research, which makes a distinction 
between a fundamental rights-based consent (ECHR, Oviedo 
Convention and EU Charter of Fundamental rights) on one 
hand, and legal bases for processing of personal data on the 
other hand (the GDPR and Clinical Trials Regulation) has fur-
ther blurred the autonomy of individuals with regard to con-
trolling the processing of their health data. We contribute to 
these discussions by pointing to the ambiguities and problems 
related to individual autonomy and to legislative weaknesses 
related to transferring and utilizing legacy samples in the Finn-
ish context. In this article, we demonstrate how in the Finn-
ish biobanks, practical operations with regard to legacy sam-
ples, and in extensio, for the overall majority of samples, the 
autonomy is reduced to the possibility of opt-out in case the 
donor happens to see the notice of the transfer published in the 
newspaper. It is likely that the donor does not have knowledge 
regarding the changed purpose of the diagnostic samples col-
lected within health care (Snell and Tarkkala 2019).
In the following, we offer a socio-legal analysis (e.g., 
Banakar and Travers 2005) of legacy samples in Finnish 
biobanking, reviewing, and reflecting on the current legisla-
tion. This is done based on publicly available materials (leg-
islation and preparatory documents) and empirical material 
dealing with sample collection of biobanks. In addition to the 
Biobank Act and its preparatory and follow-up documents, we 
also discuss how the current biobank law relating to transfer 
of legacy samples is to be regarded in light of the opinions of 
the Constitutional Law Committee of the Finnish Parliament. 
We then move on to the specific case of legacy samples, and 
present empirical data on the amounts of biobank samples 
while discussing the regulatory implications and issues raised 
in terms of social sustainability. The key international regula-
tions utilized to draw attention to specific aspects of biobank 
operations and the Finnish Biobank Act are the European Con-
vention of Human Rights, the Oviedo Convention, and the 
European Charter of Fundamental Rights as well as the GDPR 
and EU clinical trials regulation. In this sense, we show that a 
case Tupasela (2015, 380) has called “interpretive regulatory 
dissonance”. The concept refers to the way different countries 
“interpret directives and conventions in different ways”, which 
is seen to give rise to “vastly different legal applications and 
practices related to biobanking” (Tupasela 2015, 380). This is 
further accentuated by divergent national implementation of 
the GDPR rules related to scientific research posing obstacles 
to cross-border scientific research instead of facilitating it (for 
biobanking, see Slokenberga et al. 2019; for general biomedi-
cal research, see Townend 2018; Salokannel 2017). In this 
connection, some of the problems raised by this article relate 
to the fact that biobank research as defined in the current law 
encompasses also purely commercial drug and medical device 
development extending thus beyond the notion of scientific 
research as understood in biomedical research practice.
Legal basis for biobank operations 
in Finland
General principles of the Biobank Act
Biobank activities in Finland are defined by the Biobank 
Act (688/2012), which came into force in 2013. The draft-
ing of the Biobank Act was a long process that contained 
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disagreement about the content and scope of the law and was 
hampered by parliamentary elections. Initially, in 2006, a 
working group was set by the Ministry of Social Affairs and 
Health with a task to define what a biobank is and chart all 
the legislation that currently regulated biomedical research 
in Finland and elsewhere. Finally, after two rounds of com-
ments, three drafts and over 7 years, the law came into force. 
However, the process has not ended, since it became appar-
ent very quickly that there are legislative issues in need of 
clarification and the Act has been under reform since then.
The current Act regulates biobanks of all types, including 
public and private as well as clinical and epidemiological 
biobanks. According to the legislation, a biobank is a “unit 
maintained by an operator engaging in biobanking activi-
ties for the purposes of collecting and storing samples and 
information associated with the samples for future biobank 
research” [Sect. 3.1(1)].
All biobanks must apply for approval from a national 
ethical committee before they are registered as biobanks. 
In the beginning of 2014, the first two Finnish biobanks 
were established, registered, and started to operate. Since 
then, altogether, ten biobanks have been registered in the 
national database held by VALVIRA, the national supervi-
sory authority for health and welfare. The biobanks in Fin-
land are comprised of the national population-based biobank 
hosted by the National Institute of Health and Welfare, six 
biobanks operated by hospital districts, one disease-based 
biobank, the biobank of the national blood service, and one 
operated by a private health care company.
Biobank research itself is defined in the law as “research 
utilising the samples contained in a biobank or information 
associated with them for the purposes of promoting health, 
understanding the mechanisms of disease or developing 
the products and treatment practices used in health care 
and medical care” [Sect. 3.1(8)]. In other words, biobank 
research is to be understood more broadly than mere scien-
tific research, which also encompasses product development 
for general health and medical care purposes (HE 86/2011, 
p. 41). “Biobank sample” is also broadly defined as consist-
ing both of the sample as such and any information derived 
from it, such as genetic information.
A main principle of the Act (688/2012) is that informed 
consent of the donor is sought for the inclusion of samples in 
biobanks and their further use (Sect. 11 of the Biobank Act). 
The consent model has been promoted by biobank opera-
tors, the Ministry of Social Affairs and Health and at the 
policy level as one of the more positive aspects of the Act 
as it is regarded to enable a wide range of research, enhance 
the rights of the donor, and make recontacting of donors 
possible (HE 86/2011; Carpén and Helander 2017; Soini 
2016). According to the law, the broad biobank consent 
also provides for adding complementary information about, 
for example, donor’s disease history to the biobank for the 
biobank to match this sort of sensitive information with the 
donor’s personal data (Sect. 14 Biobank Act; Opinion of the 
Constitutional Law Committee 10/2012). In practice, con-
senting to adding additional register data to the biobank data 
is included in the information leaflet and no separate consent 
is asked from the donor. The preparatory documents of the 
law did, however, indicate that such separate consent should 
have been acquired (HE 86/2011).
Moreover, the Act states that the donor has a right to 
limit the consent, but the current consent forms do not give 
the option to restrict or limit the consent.1 It is an either-or 
choice for the donor, even though the GDPR emphasises 
data subjects’ right to give their consent only to certain 
areas of scientific research (Recital 33). The consent should, 
according to the current international regulatory framework, 
safeguard the autonomy and informational self-determina-
tion of the individual as guaranteed in the European Con-
vention of Human Rights, the Oviedo Convention, and the 
European Charter of Fundamental Rights.
With the entering of force of the GDPR which provides 
strict rules for consent as the legal basis for processing per-
sonal data, the regulatory authorities in Finland pointed to the 
non-compatibility of the consent used in the biobank practice 
with the more stricter rules for consent to be recognised as a 
valid legal basis for processing of personal data. Most impor-
tantly, the Finnish biobank practice did not conform with the 
requirements of the GDPR with regard to providing the data 
subject with an ability to choose whether to give a broad or 
a more limited consent (recital 43). This was the case even 
while recognising the possibility to have broad consent for 
research activities (recital 33). An attempt to solve this prob-
lem can be found within a new Finnish law on secondary 
use of social and health data (552/2019). In the transitional 
provisions of the law, it is stated that for the personal data 
collected by consent before the GDPR entered into force, the 
consent should be regarded as a valid legal basis for further 
processing presupposing that further processing relates to the 
same use as that referred to in the consent. According to the 
preparatory documents of the law, this provision is catered, in 
particular, towards biobank consents (HE 159/2017).
Legacy samples and data in Finnish 
biobanks
The so-called legacy samples—samples collected prior 
to biobank legislation—constitute the basis for the Finn-
ish biobank operations. These samples—collected for 
1 The template and content of informed consent forms has changed 
on several occasions, which means that in practice, the informed con-




diagnostic purposes in public hospitals or for research pur-
poses by the Finnish Institute of Health and Welfare—were 
identified as forming an important resource for biomedical 
research already over a decade ago (see STM 2007). When 
the process to prepare a biobank legislation in Finland was 
initiated, it was highlighted that Finland had already col-
lected samples from approximately 2 million people (STM 
2007, 20), and these samples should be made available 
for further utilization through biobanks. This was accom-
plished by providing in the law for the possibility to trans-
fer most old clinical collections as well as epidemiological 
research cohorts into new biobanks established according 
to the law.
There are two types of biological samples and related 
data which have been transferred retroactively by virtue of 
the law to Finnish biobanks: diagnostic samples and sam-
ples from research projects. These data form the majority 
of biological materials in Finnish biobanks. The biobank 
law permits
(a) transferring of diagnostic samples which have been col-
lected in connection with health care prior to entering 
of into force of the biobank law in 2013 and for which 
no consent exists2 or
(b) transfer of samples for such research projects which 
have started prior to the entering into force.3.
The actual transfer of legacy samples into biobanks has 
required permission from the regional ethical committee 
of the hospital district, where the samples are stored as 
well as from the supervisory health authority. According 
to the biobank law, the patients should be informed of the 
changed purpose related to the transfer of their samples to 
the biobank and of the option to prohibit it. However, in 
general, it has not been the custom of biobanks to re-con-
tact patients or research participants. Instead, the possibil-
ity provided in the law to publish a notice at the website of 
the biobank and some daily newspapers before the transfer 
has been considered sufficient. In the intermediary report 
by the steering group of the Biobank Act (STM 2015), it 
was acknowledged that the notification procedure does not 
comply with individuals’ informational self-determination 
rights and that steps should be made to reinforce individual 
autonomy. In practice, the situation remains the same.
The law also provides for the possibility to match related 
register data from official registers and patient records to 
these retroactively transferred samples. It has not been 
defined in the law what such data could be. The Finnish 
data protection authority and the supervisory authority have 
stressed that these data should be closely related to the spe-
cific sample (Valvira 2017).
Moreover, when biobank operations in Finland started, 
it was thought that older sample collections would be trans-
ferred into biobanks within a 5-year period. The provision 
of the law regarding the legacy samples was originally 
applied to clinical collections and research projects that had 
started before September 2013, and these transfers were to 
take place by January 2018 (HE 86/2011, 72). However, 
also quite recently, even in 2018, acquired materials have 
been transferred by virtue of this provision without consent 
from the donors, and usually without personally informing 
them about the transfers.4 From the National Institute of 
Health and Welfare biobank’s webpage, for instance, it can 
be noted that throughout 2018, transfers of older research 
collections continued to take place (THL 2019b). As noted 
above, the Biobank Act is in the process of revision. In the 
2018 draft version for a new act, it was suggested that these 
transfers could continue. Furthermore, the special proce-
dure allowing the transfers could be extended to cover even 
sample collections that were started after the enforcement 
of the current Biobank Act from 2013 (Draft for Biobank 
Act 2018, 73).
In terms of the Finnish Constitution, the large amount 
of samples and attached data transferred without explicitly 
informing the data subjects based on an exception to the law 
seems problematic. As we shall demonstrate in this article, 
the transfers of this magnitude form in reality the basis for 
the biobanking operations in Finland in contrast to what 
the pronounced intention of the law was. According to the 
Constitutional Law Committee, processing of personal data, 
which is based on an exception to the main rule (consent in 
this case), cannot become the main processing activity. The 
biobank law is also problematic when regarded in relation to 
the information obligations imposed by the Oviedo Conven-
tion and, in particular, the GDPR, as we shall demonstrate 
later in this article.
2 A health care unit that, at the time of this act’s entry into force, 
stores biological samples generated in connection with the examina-
tion and treatment of a patient (diagnostic samples) and patient doc-
uments associated with such samples may transfer the samples and 
information associated with the samples to a biobank, secrecy provi-
sions notwithstanding. The transfer must not jeopardise the provision 
and implementation of patient care (Sect. 13.1).
3 Secrecy provisions notwithstanding, an institute of higher educa-
tion, a research institute, a health care unit or some other unit may 
transfer the samples collected and analysed in connection with a 
study initiated prior to this act’s entry into force and the information 
related to them to a biobank. (Sect. 13.2)
4 As an exception to this, the National Institute of Health tweeted 
on 20.3.2019 that it had transferred a “Helsinki Heart Study” collec-
tion from the 1980 s and 1990 s through personal notifications and by 
obtaining new biobank consents from the participants (THL 2019a).
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Current status of legacy samples in Finnish 
biobank operations
Currently, there are over 10 million legacy samples in Finn-
ish biobanks. In practice, these samples and data form the 
majority of biological materials in Finnish biobanks (see 
Table 1). As the samples had been collected prior to the date, 
the legislation was put into force, no biobank consents as 
defined in the law exist for these samples. This applies both 
to the samples collected for diagnostic purposes in health 
care and samples collected for research projects that started 
before the law was in force. A majority of the research sam-
ples were collected with consents to the original research. 
This means that in practice, the foundation of the opera-
tions of the Finnish biobanking infrastructure is based on 
these legacy samples rather than on samples for which an 
explicit biobank consent has been obtained. In fact, there 
are nearly 100 times more legacy samples than new samples 
(see Table 1). Examples of such transferred legacy collec-
tions include the pathology archives of hospital districts. In 
Tampere, the biobank announced on 15th September 2017 
a notification related to the transfer of samples taken for 
diagnostic purposes between 1963 and 2013. In this case, 
the transfer concerned 1,800,000 samples. Similarly, the 
Finnish Maternity Cohort (FMC), a collection of 2 million 
serum samples, was transferred into Borealis Biobank in 
Oulu in 2017.
Mixed set of samples acquired on various 
legal bases: the case of the Finnish maternity 
cohort
One of the more illustrative examples of retrospective trans-
fer of legacy samples into a newly formed biobank concerns 
the Finnish Maternity Cohort (FMC)—a collection of serum 
samples drawn during the first and early second trimesters of 
pregnancy for the screening of HIV, syphilis, and hepatitis. 
These samples have been gathered as a routine practice in 
prenatal care and stored to the Institute of Health and Wel-
fare since 1983. The collection consists of samples from 
98% of pregnant women between 1983 and 2016—almost 
1,000,000 women. It should be noted that samples have been 
collected from nearly all women who have given birth in 
Finland during that period, including from those who are 
not Finnish nationals or who do not reside in the country 
anymore. The samples were gathered for a diagnostic pur-
pose, but were stored as a research collection based on the 
legal duty of the Institute of Health and Welfare. Only since 
2001 has there been a requirement to ask for consent for 
research use of the samples. In 2017, the FMC was trans-
ferred to Borealis Biobank in accordance with Sect. 13 of 
the Biobank Act. The transfer was announced in newspapers 
and web pages of National Institute of Health and Welfare 
(THL 2017), where it was also stated that women can opt-
out from the retrospective transfer of their samples to the 
biobank. Since the transfer, the biobank has started to ask 
for a separate consent for each sample to be donated to the 
FMC, as required by the law. However, in 2019, the Institute 
of Health and Welfare webpage only provides information 
that the collection has been transferred to Borealis, with no 
further details of opt-out possibilities or about the collection 
given.5 There is only a link to the Borealis site with a short 
description of the cohort. The text on the page tells how to 
contact the biobank in case people are uncertain whether 
their samples are in the biobank, but there is no mention of 
a possibility to opt-out.6
The consent practices and the transfer of these legacy 
samples demonstrate the many difficulties we associate with 
Finnish legislation and the rights of individuals. First of all, 
the legal status of the early samples is unclear, because the 
boundary between a research sample and a diagnostic sam-
ple is ambiguous in this case. The samples have been used 
for diagnostics and were framed for the pregnant women 
as part of routine maternity care, but have been reassigned 
as a legacy collection of research samples through the 
Table 1  Estimated number of samples and biobank consents in six 
clinical biobanks in Finland
Numbers are based partly on the e-mail responses we got from each 
biobank. Some biobanks provided exact numbers, while others only 
rough estimates. If the biobank did not respond to our queries, we 
have used figures that are from their web pages or presented in public 
presentations, and the numbers presented in a report by Medaffcon 
(2018)
Six biobanks are clinical biobanks operated by hospital districts that 
have old diagnostic sample collections and research sample col-
lections. The four biobanks left out do not have or have not trans-
ferred diagnostic collections. THL biobank of the National Institute 




 Diagnostic samples transferred 9,950,000
 Diagnostic samples on individuals 2,900,000
 Research samples transferred 980,000
 Research samples on individuals 955,000
Prospective consents and samples
 Biobank consents by the end of 2017 125,000 Data from 
all ten 
biobanks
 Consented samples by the end of 2018 108,000
5 See https ://thl.fi/fi/tutki mus-ja-kehit tamin en/tutki mukse t-ja-hankk eet/
finni sh-mater nity-cohor t-fmc-seeru mipan kki (accessed 16.5.2019).
6 https ://www.ppshp .fi/Tutki mus-ja-opetu s/Biopa nkki/Kansa laisi lle/
Pages /defau lt.aspx (accessed 16.5.2019).
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establishment of the FMC. The collection now includes 
samples stored and utilized on three different grounds: the 
majority are legacy samples without any consent; the second 
part consists of legacy samples that have been consented to, 
but the transfer to biobank has been done on legal grounds, 
and the smallest part consists of samples collected with 
informed consent.
Similar problems are faced by other biobanks and coun-
tries. Biobank Graz in Southern Austria serves as a good 
comparison to Finnish biobanks and the transfer of older 
collections. The biobank was established in 2007, and since 
then, the already existing pathology collection of the Insti-
tute of Pathology as well as clinical collections within the 
Medical University of Graz have been transferred to the 
biobank with oldest samples dating back to 1984 (Hup-
pertz et al. 2016, 1–2). This biobank of 7.5 million samples 
from over 1 million people (Huppertz et al. 2016, 1, 4) has 
also needed to adapt to requirements and recommenda-
tions concerning the usage of legacy samples (see, e.g., 
Federal Chancellery of the Republic of Austria, 2007). 
For example, part of the legacy samples in Graz can be 
used only as anonymized, since their transfer took place 
before clarifications for the usage of legacy samples by 
the national bioethics committee and was published (Hup-
pertz et al. 2016, 4). Despite the shared challenge of the 
bases on which the legacy collections can be put in use, 
there are differences as well. In Graz, the biobank can only 
link indirect person-related clinical data with the samples. 
The direct person-related data are linked with the sample 
by university-based and biobank independent custodian. 
Moreover, the ethical approval of the biobank is renewed 
annually to “assure that ethical guidelines are followed any 
time” (Huppertz et al. 2016, 3). Such safeguards are not in 
place in Finland.
In the following, we analyse specific issues relating to 
Finnish biobank operations, the Biobank Act, and their 
relations to the EU General Data Protection Regulation 
and the related European human rights and fundamental 
rights framework, in particular, as they relate to informing 
data subjects of the use of their data. We will discuss the 
GDPR only and not the data protection directive 95/46/EC, 
although the information obligations were largely similar 
also under the Directive 95/46/EC. First, we analyse how 
the principle of purpose limitation is being overridden with 
regard to legacy sample collections. This highlights the fact 
that the legislation has not been able to guarantee a legally 
precise or coherent framework for biobank operations, but 
the purposes and the principles behind the law as stated 
in the preparatory documents have not been followed in 
practice.
Right to privacy and data protection 
according to the European rights framework
According to the Article 8 of the European Convention 
on Human Rights and Fundamental Freedoms (ETS 005), 
hereinafter ECHR, everyone has the right to respect for his 
private and family life. The convention prohibits any inter-
ference by a public authority with the exercise of this right 
except such
(a) as is in accordance with the law;
(b) is necessary in a democratic society in the interests of 
national security, public safety or the economic well-
being of the country, for the prevention of disorder or 
crime, for the protection of health or morals, or for the 
protection of the rights and freedoms of others.
Furthermore, the convention provides that the exercise of 
freedom of expression may be restricted for preventing the 
disclosure of information received in confidence (Art. 10.2). 
This is relevant in so far that health information is subject to 
strict confidentiality according to the Finnish Act on access 
to official documents (Law 621/99) and according to the Act 
on patients’ status and rights (Law 785/92). In consequence, 
patients expect that their health information remains confi-
dential within the health care sector.
The Oviedo Convention,7 which is complemented by a 
number of protocols in which its principles are further elabo-
rated and complemented with regard to specific subjects, 
further reaffirms the application of the fundamental human 
rights in relation to the integrity of persons in the field of 
biomedicine. It sets the interests and welfare of the human 
being over the sole interest of society or science (Art. 2). 
This means that when interpreting the convention, the inter-
ests of the individual person shall prevail over the interests 
of the society and research.8
According to the convention, any intervention in the field 
of medicine must be based on informed and freely given 
consent by the patient (Art. 5). With respect to scientific 
research, it is required that such consent is expressly given 
and that it is specific and documented. The research subjects 
must be informed beforehand of their rights and the safe-
guards provided by law for their protection (Art. 15 and 16).
The Convention also provides that the right to respect of 
private life extends to the information relating to person’s 
health. The Convention further confirms that everyone is 
7 Convention for the protection of Human Rights and Dignity of the 
Human Being with regard to the Application of Biology and Medi-
cine: Convention on Human Rights and Biomedicine, ETS 164.
8 Additional Protocol to the Convention on Human Rights and Bio-
medicine, concerning Biomedical Research, CETS 195, para. 21.
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entitled to know any information collected about her health. 
This is subject to person’s wish not to be informed. In addi-
tion, in exceptional cases and in the interest of the patient, 
the law may restrict person’s right to know about health (Art. 
10). This article affirms the right to privacy of the patient 
as well as the right to informational self-determination over 
the data related to her health. The article is based on the 
Article 8 of the European Human Rights Convention and 
more broadly also on the Council of Europe Convention for 
the protection of individuals with regard to the processing of 
personal data.9 Finland has ratified both these conventions 
as well as the Oviedo Convention.
The enforcement of the Oviedo Convention relies on the 
provisions of the ECHR (Art. 32) and, consequently, on the 
European Court of Human Rights. While contracting parties 
commit themselves to insert in their national legislations 
necessary measures to give effect to the provisions of the 
Oviedo Convention and its protocols, it does not as such 
provide an enforcement mechanism in case member states 
overlook its provisions in their national laws. However, the 
European Court of Human Rights has the possibility to take 
into consideration the principles adopted in the Oviedo Con-
vention in its judgments.10 To do that, this requires a viola-
tion of the rights provided for in the ECHR. In addition, 
the Court may issue advisory opinions on legal questions 
relating to the interpretation of the Oviedo Convention on 
request of the government of a member state or on request by 
the Committee setup according to Art. 32 Oviedo Conven-
tion according to the procedures provided for in Article 29, 
Oviedo Convention.
The EU Charter of Fundamental rights confirms the prin-
ciples of the human rights conventions. The right to human 
dignity forms the core of human rights protection and is 
inviolable (Art.1). Right to the respect of the integrity of the 
person means that everyone has the right to respect for her 
physical and mental integrity. In the field of medicine and 
biology, this means in particular that the free and informed 
consent of the person concerned according to the procedures 
laid down by law must be respected [Art 3.2(a)]. Right to 
privacy is guaranteed in the Article 7 of the Charter and 
right to data protection in article 8. Processing of health-
related data relates to all of these rights. Article 8 of the 
Charter constitutes the essential content of the right to data 
protection which may be restricted only when the require-
ments of Article 52.1 of the Charter are fulfilled. This article 
must be interpreted in light of the case law of the European 
Court of Human Rights.11
In Finland right to privacy is guaranteed in the Article 
10.1 of the Finnish Constitution in which it is provided that 
more specific legislation relating to data protection shall be 
provided by law. With regard to protection of health-related 
data, the Constitutional Law Committee of the Finnish Par-
liament has adopted a strict interpretation and considers the 
processing of health and other sensitive data as belonging 
to the core of data protection (cf. PeVL 37/2013 vp). This 
further restricts the legislator insofar that it always has to 
take into account of the right to privacy as conferred under 
the Finnish Constitution and in the European Constitutional 
context (see, e.g., the opinions of the Constitutional Law 
Committee PeVL 13/2016 vp, s. 3—4 PeVL 1/2018, s. 3).
This means that when considering the legal framework 
in regard to the processing of health data, including genetic 
data, of the individual, it is not sufficient to take into account 
of only the GDPR and complementary national legislation, 
but also the international human rights conventions, includ-
ing the Oviedo Convention as well as the Charter of Funda-
mental Rights and other related EU legislation such as the 
Clinical Trials Regulation [Regulation (EU) No: 536/2014].
Right to information of the data subject
Right to information forms the very basis of the European 
privacy and data protection regulatory framework. With 
regard to data protection, it should safeguard the trans-
parency of the processing. The data subject must be in a 
position to know when his or her personal data are being 
processed to enforce her rights according to the law.12 
According to the transparency guidelines of the WP29,13 
data subjects should be able to determine in advance what 
the scope and consequences of the processing are and should 
not be taken by surprise at a later point about the ways in 
which their personal data have been used. Thus, the transpar-
ency of the processing can be characterised as forming the 
underlying basis for any exercise of the rights of the data 
subject. As stated by Advocate General Cruz Villalon (9 
9 At 63, Explanatory Report to the Convention for the protection of 
Human Rights and Dignity of the Human Being with regard to the 
Application of Biology and Medicine: Convention on Human Rights 
and Biomedicine, 1997.
10 Seatzu (2015).
11 For the interplay of CoE Conventions and the GDPR, see also 
Bygrave (2017), available at https ://www.idunn .no/oslo_law_revie 
w/2017/02/data_prote ction _by_desig n_and_by_defau lt_decip herin 
g_the_.
12 Bygrave (2017).
13 WP29 was an advisory body that preceded the European Data Pro-
tection Board before the enactment of the GDPR.
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July 2015),14 “the requirement to inform the data subjects 
about the processing of their personal data, which guarantees 
transparency of all processing, is all the more important, 
since it affects the exercise of their right of access to the data 
being processed and their right to object to the processing 
of those data, as set out in Article 14 of Directive 95/46.” 
This also makes it clear that the information obligation was 
of fundamental importance already under Directive 95/46. 
In this sense, transparency of the processing is the basis for 
guaranteeing the autonomy and informational self-determi-
nation of the individual.
In a similar line with regard to biomedical research, the Pro-
tocol on Biomedical research to the Oviedo Convention requires 
for a consent to be regarded as valid when the donor has been 
informed of all his or her rights relating to the research and of 
the safeguards offered by the law.15 When the transfer has been 
carried out without explicit consent and with the notification 
only, it has been questioned whether the donor can be consid-
ered informed (Snell and Tarkkala 2019; cf. Caulfield and Mur-
doch 2017). The protocol provides for detailed stipulations with 
regard to the information to be submitted to the research subject, 
while the GDPR as we shall show later is even stricter with its 
mandatory provisions on informing data subjects.
The information obligation portion of the Protocol to the 
Oviedo Convention explicitly covers information relating to 
the further uses of data obtained from research. The proto-
col expressly provides for the submission of information for 
any foreseen potential further uses, including commercial 
uses, of the research results, data or biological materials. 
This potential commercial use is provided for in the Finnish 
Biobank Act and the donors should be informed accord-
ingly. In respect to highlighting the importance of inform-
ing subjects whether the further uses of the results, data or 
biological materials are part of commercial product develop-
ment, the explanatory memorandum refers to the recital 26 
of Directive 98/44/EC, which states that
“if an invention is based on biological material of 
human origin or if it uses such material, where a pat-
ent application is filed, the person from whose body 
the material is taken must have had an opportunity 
of expressing free and informed consent thereto, in 
accordance with national law”.16
This refers to the availability of research results and the 
eventual IPR-related arrangements related to the research 
project. The protocol explicitly states that the information 
given to the data subjects must also contain information 
about the source of research funding.
While information leaflets of the broad biobank consents 
do mention commercial product development with local and 
international partners, the general announcements in local 
newspapers relating to the transfer of old epidemiological 
collections do not necessarily indicate that. In addition, the 
content of the newspaper announcement is often hard to 
verify in retrospect with regard to many of the transfers, 
since the public announcements are not always permanently 
available on the webpages of the biobanks.
Another important point in the Oviedo Convention in the 
context of biobanking relates to biological material removed 
in connection with clinical intervention. The explanatory 
report of the Protocol on Biomedical research states that 
if there is an intention to utilize biological materials or 
personal data obtained during a medical intervention for 
research purposes after the medical intervention, it is good 
practice to obtain a specific consent for such research uses 
not related to the medical intervention.17 This principle is 
also confirmed in the EU Clinical Trials Regulation (No. 
536/2014 EU), which explicitly requires a separate con-
sent for subsequent research use of trial data.18 Thus, these 
principles are elementary both for the legacy samples based 
on clinical collections of hospitals, and the ones based on 
research projects. This principle is confirmed at the regu-
latory level in EU clinical trials regulation, which distin-
guishes between the consent for participating in the clinical 
trial on one hand, and consent relating to further research 
uses of data derived from such trial on the other hand. These 
consents would, according to the guidelines of the European 
Data Protection Board, be based on the international human 
rights and EU fundamental rights frameworks and the Clini-
cal Trials Regulation, whereas the legal basis for the actual 
processing of the personal data would be based on Articles 
6 and 9 of the GDPR.19
Right to information of data subjects 
relating to transfer of legacy samples 
to biobanks in terms of the Finnish biobank 
law
The transfer of the legacy collections to biobanks entails a 
change of purpose for samples originally collected for diag-
nostic purposes. In addition, for larger research cohorts, the 
17 Explanatory Report, CETS 195, 78.
18 Art. 28.2, EU Clinical Trials Regulation EU No. 536/2014.
19 Opinion 3/2019 concerning the Questions and Answers on the 
interplay between the Clinical Trials Regulation (CTR) and the Gen-
eral Data Protection regulation (GDPR) (art. 70.1.b), 23 Jan. 2019.
14 Opinion of Advocate General Cruz Villalon (9 July 2015) in the 
Bara case (Case C-201/14) referring to application of Art. 12 of 
Directive 95/46, at 74.
15 Art. 5 ja 16 Oviedo Convention and Art. 14 Protocol as well as 
expl. memorandum at 102. Finland has not ratified the Protocol.
16 Recital 26 of Directive 98/44/EC of the European Parliament and 




purpose is being changed to the extent that biobank research 
according to the law also encompasses commercial product 
development. Transfers of these collections have occurred by 
announcing them in major newspapers. While only intended 
as a last option, this has become that the main procedure 
biobanks have chosen to use. This is rather surprising, 
given that the hospitals have the contact information of their 
patients at hand. This is even more surprising relating to 
transfer of samples from longitudinal studies, since in these 
studies, the patients are often contacted periodically. The 
biobanks also attach other personal information relating to 
the individual from these very registers.
The preparatory documents of the biobank law (HE 
86/2011) indicate that the underlying purpose of the law is 
to inform the data subjects of the change of purpose of the 
diagnostic samples and their further use. It is even stated 
that since the hospital districts are already in possession of 
the contact information of these patients, it would be easy 
to get in touch with them by electronic means. The infor-
mation is also available in the national population register. 
Clearly, in light of the preparatory documents, the controller 
was expected to inform the data subjects individually when 
retroactively transferring biological materials from hospital 
collections to a biobank (HE 86/2011, 53). Not contacting 
the data subjects whose contact information was available 
for the data controllers would also run counter to the infor-
mation requirements of Article 13 GDPR.
Data subject’s right to know about the eventual transfer of 
their diagnostic samples for further use in connection with 
biobank operations was not, however, included in the text of 
the law. Rather, on the contrary, the biobank law provides 
for the option to derogate from personally informing the 
data subjects in case the age or large number of the samples, 
or some other similar reason, which makes it burdensome 
to obtain the contact information of a registered individual 
with a reasonable effort. In this case, the notification must 
be published in an official paper, in a public communica-
tion network or, as necessary, in one or more daily papers 
(Sect. 13.4 Biobank Act). This also requires the approval of 
the Supervisory Health Authority. In practice, the notices 
have been published in a daily newspaper and they have been 
put up on the webpage of the biobank either permanently 
or for some months, after which they have been removed. 
Practices in this respect vary between biobanks.
There are numerous reasons why the sufficiency of noti-
fication procedure can be put under scrutiny. In terms of 
Article 13 of the GDPR, the original controller of biologi-
cal materials of hospital collections should inform the data 
subjects about the changed purpose of these materials and of 
their right to prohibit their transfer to the biobank. Since the 
original controller of these materials is the hospital district, 
it should inform the data subjects of the changed purpose of 
these materials and of their possibility to prohibit the said 
transfer to the biobank. They should also be given infor-
mation about the eventual further processing of personal 
data before any such further processing takes place. Further-
more, with regard to retroactively transferred samples from 
research cohorts in which there is no changed purpose in 
relation to scientific research, there is a changed purpose if 
those samples or the data are used for product development 
or other types of innovation purposes (STM 2015).
The GDPR also requires biobanks to inform data sub-
jects in case the personal data would be transferred to a 
recipient in a country outside of the EEA or international 
organisation. These requirements are the same irrespective 
of whether the data are obtained directly from the data sub-
ject or from other sources.
The possibilities for making exceptions to the require-
ments relating to informing the data subjects differ in rela-
tion to whether the data are obtained directly from the data 
subject or from some other source. If the data have been 
obtained directly from the data subject, the only permissible 
exception to the information requirements is that the data 
subject already has all the information. Even in this case, 
over time, supplementary information has to be provided 
subject to changed circumstances. Thus, the GDPR has strict 
information obligations for the processing of personal data 
and its utilization for secondary uses more widely. As we 
argue throughout this article, this is a challenge for biobank 
practice of transferring legacy collections to biobanks.
GDPR does not permit any derogations with regard to 
article 13 even if the data are used for scientific research. 
The only possibility to override the information obligation 
would be under Article 23 which would require that such 
restriction
(a) is performed by a legislative measure;
(b) respects to the essence of the fundamental rights and 
freedoms;
(c) is a necessary and proportionate measure to safeguard.
One of the interests provided for in Art 23.2 is, public 
health. The application of this article is limited by the Char-
ter of Fundamental Rights, according to which the scope 
of guaranteed rights and any limitation on the exercise of 
the rights and freedoms recognised by the Charter must be 
provided for by law and respect the essence of those rights 
and freedoms. Subject to the principle of proportionality, 
limitations may be made only if they are necessary and 
genuinely meet objectives of general interest recognised 
by the Union or the need to protect the rights and free-
doms of others. Moreover, the Charter refers to the CoE 
Human Rights Convention for determining the meaning and 
scope of those rights when they correspond to the rights 




The European Court of Human Rights has an established 
case law relating to what is to be considered as necessary 
in a democratic society in relation to restricting the right to 
privacy. According to the Court, what is necessary in terms 
of this article may not be interpreted as meaning what is use-
ful, reasonable, or desirable, but it refers to pressing social 
need as a prerequisite for limiting the right to privacy. Any 
such legislative measure has to reflect a pressing social need 
and be proportionate to the legitimate aim for such measure.
In its decision Z v Finland the European Court of 
Human Rights states that “In determining whether the 
impugned measures were “necessary in a democratic 
society”, the Court will consider whether, in the light 
of the case as a whole, the reasons adduced to jus-
tify them were relevant and sufficient and whether the 
measures were proportionate to the legitimate aims 
pursued. In this connection, the Court will take into 
account that the protection of personal data, not least 
medical data, is of fundamental importance to a per-
son’s enjoyment of his or her right to respect for pri-
vate and family life as guaranteed by Article 8 of the 
Convention.
Respecting the confidentiality of health data is a vital 
principle in the legal systems of all the Contracting 
Parties to the Convention. It is crucial not only to 
respect the sense of privacy of a patient, but also to 
preserve his or her confidence in the medical profes-
sion and in the health services in general. Without such 
protection, those in need of medical assistance may be 
deterred from revealing such information of a personal 
and intimate nature as may be necessary to receive 
appropriate treatment, and even from seeking such 
treatment, and thereby endangering their own health 
and in case of transmissible diseases, that of the com-
munity (Z v. FINLAND—22009/93 [1997] ECHR 10 
(25 February 1997)).
This would mean that, when applied to the restriction of 
the right to information of data subjects, there would have 
to exist a pressing social need for such derogation. This 
is hardly the case with regard to overlooking informing 
the data subjects of the transfer of diagnostic samples to 
biobanks for various further uses.
Conclusions regarding the current biobank 
operations and discussion on future 
challenges
The Finnish biobanking system and the Biobank Act have 
been promoted internationally as one of the more advanced 
biobanking systems in the world. The broad consent, 
possibility to re-contact, and willing and positively inclined 
population have been identified as key components of 
achieving success (Snell and Tarkkala 2019). We aimed 
to demonstrate that the complex and changing regulatory 
framework creates a situation of “interpretive regulatory 
dissonance” (Tupasela 2015), where different countries and 
biobanks interpret the international and EU-level regulatory 
framework in a different way. What is articulated in public 
and how the law is applied in practice can also differ drasti-
cally. We show that the core of Finnish biobanking is formed 
on legacy samples that are transferred to biobanks without 
consent of donors and without their knowledge of the trans-
fers. That is, even though biobanks collect prospective sam-
ples with consents; in practice, biobanks operate mostly with 
samples that have been transferred to their collections with a 
notification procedure consisting of a public announcement. 
These approximately 10 million legacy samples, for now, 
form the core of the actual biobanking operations, compared 
to the under 200,000 samples with biobank consent.
Even if acknowledging that similar transfers have taken 
place elsewhere, such as in Graz, the Finnish practice can be 
seen as exceptional because of the way these legacy collec-
tions were and continue to be transferred into biobank collec-
tions, while at the same time, informed consent and respect of 
individual autonomy are advertised by biobanks and in poli-
cies as the cornerstone of Finnish biobanking (Snell 2019). 
The people can hardly be expected to know that their samples 
are being stored, which make their ability to opt-out illusory 
(Snell and Tarkkala 2019). If people are not aware of the 
transfer or do not even know that their diagnostic samples 
have been saved at the hospital, the opt-out offered in connec-
tion with these transfers does not have real meaning.
While the autonomy of the individual is being obfus-
cated with the transfer of legacy samples to biobanks, it has 
also been set under strain by the GDPR which provides that 
authorities should not base their processing on consent, but 
should rather have a different legal basis, that is a law or 
public interest, for their processing activities. This is due to 
the unquestionable imbalance of power between the author-
ity and the data subject as stated in the GDPR, according 
to which consent should not provide a valid legal ground 
in a specific case, where there is a clear imbalance between 
the data subject and the controller, in particular, where the 
controller is a public authority (GDPR, Recital 43; cf. also 
Ruppert et al. 2017). While a sound policy in the public 
sector in general, this has created confusion in the biomedi-
cal research sector, where traditionally consent has been 
regarded as the sine qua non condition for the processing of 
personal data. The EU commission has acquired the opin-
ion of the European Data Protection Board regarding the 
very issue, and according to the EDPB, we should make a 
distinction between a consent based on the Human and Fun-
damental Rights treaties and the legal basis relating to the 
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processing of personal data according to the GDPR (EDPB 
Opinion 3/2019). As we have demonstrated, in the research 
sector, both are applicable.
We believe that consent should not be completely aban-
doned as the legal basis for processing of biological material 
and genetic data for biomedical research, because with new 
consent models, such as the dynamic consent, it is possible 
to draft the consent in a way that it respects the requirements 
of the GDPR.20 Moreover, at the international level, consent 
is still the prevailing basis for processing personal data for 
biomedical research.
If the data processing for research purposes as such is 
based on law, the autonomy of the individuals could, at least 
to a certain extent, be respected by giving them a possibility 
to opt-out of further processing of their data via a perma-
nent opt-out register. Such registers exist, for example, in 
Denmark and Norway. Article 21 of the GDPR permits only 
objecting to certain types of processing in individual cases 
and even rules out this for scientific research in case the 
processing is necessary for the performance of a task car-
ried out for reasons of public interest (Art. 21.6). An opt-out 
register could thus be conceived in terms of the GDPR as a 
safeguard for the rights and freedoms of the individual with 
regard to processing of health-related data and genetic data 
and as a complement to the consent otherwise required by 
the CoE Human Rights Convention and the Oviedo Con-
vention. Moreover, it could work as a way to introduce data 
minimisation principles to these large governmental data 
collections (EDPS Opinion 10/2017).
In Finland, setting up a permanent opt-out register within 
the national centralised electronic health record system 
Kanta could be a solution and this was even proposed in 
the preparatory and follow-up documents of the law (STM 
2015). However, no such register has been set up. Rather on 
the contrary, it has been proposed with regard to biological 
samples and genetic data collected within health care that 
they would automatically be transferred to biobanks. This 
demonstrates that the Finnish biobank consent model and 
principles for sample gathering are not fixed yet. A draft 
for a revised biobank law presenting these new ways of 
acquiring samples was presented in 2018, and a new draft is 
expected to be published in 2019.
As the legacy samples have been available for use, since 
their transfer to biobanks starting from 2014, establishing an 
opt-out register now does not remove data from already-con-
cluded projects, but it would, when accompanied by effec-
tive notification procedure at the launching stage, prevent 
any further use of those samples in biobanking operations 
without the knowledge of the data subjects. Furthermore, 
individuals could be notified of new research projects giv-
ing thus the data subjects a possibility to object on the use 
of their data in a given project or all future projects. The 
autonomy of individuals in terms of deciding over parts of 
their bodies, including the data derived thereof, could thus 
be restored.
As there is a thrust to be competitive and create an envi-
ronment enabling biomedical research and development, 
it does seem that the biobank law was required in Finland 
because of the need to amass large amounts of health data 
derived from biological materials for not only scientific 
research, but also for product development and innovation 
purposes. In the recent government data policy report (VNS 
2018), the biobank act was depicted as “internationally suc-
cessful enabling regulation”. Moreover, contrary to what 
we have argued here, the Biobank Act was seen to simulta-
neously promote both international and national biomedi-
cal research, and “autonomy and privacy of individuals” 
(VNS 2018, 10). In this report, the Finnish Biobank Act 
was viewed as based on transparency and openness. It was 
also believed to have raised awareness about the ways that 
register data are used and engage individuals to manage their 
own data. As we have demonstrated, the practice of Finn-
ish biobank operations does not fully support these claims. 
Quite the contrary, the regulatory environment seems to 
require more transparency, openness, and communication 
as well as reform to meet the higher standards of the GDPR.
Finnish biobank operations are from a legal point of 
view disconnected from the text of the law. The law sets the 
requisites with regard to the rights of data subjects in very 
general terms, and underlying meanings remain buried in 
preparatory works. This presents a perfect example why core 
principles with regard to the rights and duties of different 
parties must be provided for in the actual text of the law, in 
this case the Biobank Act, to have real meaning in practice 
and be binding in terms of enforcement. As for the future, 
the current lacunas in informing the data subjects can be 
corrected by providing data subjects with a real possibility 
to know about and control the use of their biological samples 
and data in biomedical research. In addition to providing 
legal security for all the involved parties, this would also 
work against losing the trust of the population in biobank 
operations and biomedical research in general.
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